Number of rehospitalizations occurring within 30 days of discharge from an acute care hospital (prospective payment system (PPS) or critical access hospital (CAH)) per 1000 FFS Medicare beneficiaries at the state and community level by quarter and year.
To assess the use of and persistence to ACE inhibitors or Angiotensin receptor blockers (ARB) among members with CAD or other atherosclerotic vascular disease (i.e., peripheral arterial disease, atherosclerotic aortic disease and carotid artery disease) who are at high risk for coronary events during a one year period. High-risk comorbidities are defined as heart failure, hypertension, diabetes, or chronic kidney disease (excluding stage V and patients on dialysis).
The proportion of encounters at which antibiotics prescribed to patients aged 2 months to 12 years for Acute Otitis Media (AOM) conform to the AAP/AAFP recommendation for first-line use of amoxicillin.
The measure addresses adherence to three types of chronic medications: statins, levothyroxine, and angiotensin converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs). The measure is divided into three submeasures:
Measure A: The percentage of eligible individuals who had at least two prescriptions for statins and who have a Proportion of Days Covered (PDC) of at least 0.8 during the measurement period (12 consecutive months).
Documents whether provider has adopted a qualified e-Prescribing system and the extent of use in the ambulatory setting.
The Consumer Assessment of Healthcare Providers and Systems (CAHPS) Clinician & Group Survey 3.1 (CG-CAHPS) is a standardized survey instrument that asks patients to report on their experiences with primary or specialty care received from providers and their staff in ambulatory care settings over the preceding 6 months. CG-CAHPS Survey Version 1.0 was endorsed by NQF in July 2007 (NQF #0005) and version 2.0 received maintenance endorsement in early 2015. Version 3.0 was released in July 2015 and was last endorsed in 2019.
The Consumer Assessment of Healthcare Providers and Systems (CAHPS) Clinician & Group Survey 3.1 (CG-CAHPS) is a standardized survey instrument that asks patients to report on their experiences with primary or specialty care received from providers and their staff in ambulatory care settings over the preceding 6 months. CG-CAHPS Survey Version 1.0 was endorsed by NQF in July 2007 (NQF #0005) and version 2.0 received maintenance endorsement in early 2015. Version 3.0 was released in July 2015 and was last endorsed in 2019.
The Consumer Assessment of Healthcare Providers and Systems (CAHPS) Clinician & Group Survey 3.1 (CG-CAHPS) is a standardized survey instrument that asks patients to report on their experiences with primary or specialty care received from providers and their staff in ambulatory care settings over the preceding 6 months. CG-CAHPS Survey Version 1.0 was endorsed by NQF in July 2007 (NQF #0005) and version 2.0 received maintenance endorsement in early 2015. Version 3.0 was released in July 2015 and was last endorsed in 2019.
The Consumer Assessment of Healthcare Providers and Systems (CAHPS) Clinician & Group Survey 3.1 (CG-CAHPS) is a standardized survey instrument that asks patients to report on their experiences with primary or specialty care received from providers and their staff in ambulatory care settings over the preceding 6 months. CG-CAHPS Survey Version 1.0 was endorsed by NQF in July 2007 (NQF #0005) and version 2.0 received maintenance endorsement in early 2015. Version 3.0 was released in July 2015 and was last endorsed in 2019.
The Consumer Assessment of Healthcare Providers and Systems (CAHPS) Clinician & Group Survey 3.1 (CG-CAHPS) is a standardized survey instrument that asks patients to report on their experiences with primary or specialty care received from providers and their staff in ambulatory care settings over the preceding 6 months. CG-CAHPS Survey Version 1.0 was endorsed by NQF in July 2007 (NQF #0005) and version 2.0 received maintenance endorsement in early 2015. Version 3.0 was released in July 2015 and was last endorsed in 2019.